We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

8 hedge funds and large institutions have $218K invested in Phio Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

33% more funds holding

Funds holding: 6 → 8 (+2)

1.08% less ownership

Funds ownership: 2.85% → 1.77% (-1.1%)

27% less capital inflows, than outflows

Capital inflows: $165K | Capital outflows: $226K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
+$84.7K
2
GSA Capital Partners
GSA Capital Partners
United Kingdom
+$50.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$28.8K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$1.27K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$127K
2
Wedbush Securities
Wedbush Securities
California
-$73K
3
UBS Group
UBS Group
Switzerland
-$24.9K
4
Valeo Financial Advisors
Valeo Financial Advisors
Indiana
-$1K
5
HSBC Holdings
HSBC Holdings
United Kingdom
-$509

PHIO Hedge Fund Activity: Q3 2020 in Review

8 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2020, worth a combined $218K — down 24% from $285K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new PHIO positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $84.7K. The largest seller was Renaissance Technologies, cutting an estimated $127K.

  • 8 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2020, up from 6 in Q2 2020.
  • Funds reported $218K of Phio Pharmaceuticals stock for Q3 2020, down 24% quarter-over-quarter.
  • 4 funds opened new Phio Pharmaceuticals positions in Q3 2020 and 2 closed out, a net change of +2 holders.
  • The largest Phio Pharmaceuticals buyer in Q3 2020 was Virtu Financial, an estimated $84.7K added.
  • The largest Phio Pharmaceuticals seller in Q3 2020 was Renaissance Technologies, an estimated $127K sold.

Based on aggregated 13F filings for Q3 2020.